RxDoctor Payments Data

Jenna Seets

Family · Ringgold, LANPI 1023585635

Payments from drug & device makers

$817in general payments, 2019–2025

Across 28 payments — averaging $29.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$250
  • AbbVie$167
  • Astellas Pharma US Inc$114
  • Amgen$72
  • Corium, LLC$48
  • Sunovion Pharmaceuticals Inc.$36
  • plus $129 from 7 others

What the payments were for

  • Food & beverage$71888%
  • Education$9912%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$817 in reported general payments places this provider in the 55th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$1,413
Medicare patients
37
Services billed
188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide307$313,733
OzempicSemaglutide55$68,184
EliquisApixaban37$40,145
JardianceEmpagliflozin32$32,125
LinzessLinaclotide21$19,438
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$17,398
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt14$14,405
Tresiba Flextouch U-100Insulin Degludec13$10,886
Breo ElliptaFluticasone/Vilanterol16$8,848
SymbicortBudesonide/Formoterol Fumarate15$4,460
Albuterol Sulfate HfaAlbuterol Sulfate98$3,289
Gabapentin190$2,479
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,302
Amlodipine-ValsartanAmlodipine Besylate/Valsartan46$2,105
Diclofenac Sodium49$1,715

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$250$313,733307 claims
PfizerEliquis$18$40,14537 claims
AbbVieLinzess$167$19,43821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,610 family providers in Louisiana.

Other family in Ringgold

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →